celecoxib has been researched along with Dyspepsia in 12 studies
Dyspepsia: Impaired digestion, especially after eating.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability." | 9.10 | Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. ( Burke, TA; Eisen, GM; Geis, GS; Goldstein, JL; Lefkowith, J; Peña, BM, 2002) |
| "To test whether the chronic users of celecoxib, a selective cyclo-oxygenase-2 inhibitor, had less Helicobacter pylori-related intestinal metaplasia or if such users' intestinal metaplasia could be prone to disappear after H." | 7.74 | Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. ( Cheng, HC; Hung, KH; Liou, MF; Sheu, BS; Wu, JJ; Yang, HB, 2007) |
| " There was no significant difference in the incidence of adverse events (AEs), SAEs, and discontinuations due to AEs; however, the incidence of gastrointestinal AEs in OA patients treatment with celecoxib is significantly higher than that with placebo." | 6.53 | Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. ( Gu, K; Hou, Y; Xu, C; Yasen, Y, 2016) |
| "Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| "To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability." | 5.10 | Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. ( Burke, TA; Eisen, GM; Geis, GS; Goldstein, JL; Lefkowith, J; Peña, BM, 2002) |
| "To determine the upper gastrointestinal (GI) tolerability of celecoxib, naproxen, and placebo in patients with rheumatoid arthritis (RA) and osteoarthritis (OA)." | 5.09 | Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. ( Agrawal, NM; Bensen, WG; Burke, TA; Geis, GS; Makuch, RW; Maurath, CJ; Zabinski, RA; Zhao, SZ, 2000) |
| "Ursodeoxycholic acid has a limited therapeutic role in functional dyspepsia." | 4.31 | Potential therapeutic benefit of ursodeoxycholic acid in the management of non hepato-biliary upper gastrointestinal disorders. ( Khayyat, YM, 2023) |
| "To test whether the chronic users of celecoxib, a selective cyclo-oxygenase-2 inhibitor, had less Helicobacter pylori-related intestinal metaplasia or if such users' intestinal metaplasia could be prone to disappear after H." | 3.74 | Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. ( Cheng, HC; Hung, KH; Liou, MF; Sheu, BS; Wu, JJ; Yang, HB, 2007) |
| " There was no significant difference in the incidence of adverse events (AEs), SAEs, and discontinuations due to AEs; however, the incidence of gastrointestinal AEs in OA patients treatment with celecoxib is significantly higher than that with placebo." | 2.53 | Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. ( Gu, K; Hou, Y; Xu, C; Yasen, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Khayyat, YM | 1 |
| Lee, S | 1 |
| Kim, JG | 1 |
| Kim, HJ | 1 |
| Xu, C | 1 |
| Gu, K | 1 |
| Yasen, Y | 1 |
| Hou, Y | 1 |
| Raynauld, JP | 1 |
| Martel-Pelletier, J | 1 |
| Beaulieu, A | 1 |
| Bessette, L | 1 |
| Morin, F | 1 |
| Choquette, D | 1 |
| Haraoui, B | 1 |
| Abram, F | 1 |
| Pelletier, JP | 1 |
| Cryer, BL | 1 |
| Sostek, MB | 1 |
| Fort, JG | 1 |
| Svensson, O | 1 |
| Hwang, C | 1 |
| Hochberg, MC | 1 |
| van der Bijl, P | 2 |
| Goldstein, JL | 2 |
| Zhao, SZ | 2 |
| Burke, TA | 3 |
| Palmer, R | 1 |
| von Allmen, H | 1 |
| Henderson, SC | 1 |
| Chan, FK | 1 |
| Hung, LC | 1 |
| Suen, BY | 1 |
| Wong, VW | 1 |
| Hui, AJ | 1 |
| Wu, JC | 1 |
| Leung, WK | 1 |
| Lee, YT | 1 |
| To, KF | 1 |
| Chung, SC | 1 |
| Sung, JJ | 1 |
| Lai, KC | 1 |
| Chu, KM | 1 |
| Hui, WM | 1 |
| Wong, BC | 1 |
| Hu, WH | 1 |
| Wong, WM | 1 |
| Chan, AO | 1 |
| Wong, J | 1 |
| Lam, SK | 1 |
| Yang, HB | 1 |
| Cheng, HC | 1 |
| Sheu, BS | 1 |
| Hung, KH | 1 |
| Liou, MF | 1 |
| Wu, JJ | 1 |
| Bensen, WG | 1 |
| Zabinski, RA | 1 |
| Makuch, RW | 1 |
| Maurath, CJ | 1 |
| Agrawal, NM | 1 |
| Geis, GS | 2 |
| Eisen, GM | 1 |
| Peña, BM | 1 |
| Lefkowith, J | 1 |
2 reviews available for celecoxib and Dyspepsia
| Article | Year |
|---|---|
Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials.
Topics: Abdominal Pain; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Diarrhea; Dyspepsia; Headache; | 2016 |
Non-steroidal anti-inflammatory drugs in orofacial pain management--an update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Interactions; Dy | 2002 |
6 trials available for celecoxib and Dyspepsia
| Article | Year |
|---|---|
Efficacy of Aceclofenac and Ilaprazole Combination Therapy versus Celecoxib Monotherapy for Treating NSAID-Induced Dyspepsia in Lumbar Spinal Stenosis Patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Double-Blind Method; Dyspepsia; Humans; Prospect | 2023 |
A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cycl | 2011 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspe | 2004 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyg | 2000 |
Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Double-Blind | 2002 |
4 other studies available for celecoxib and Dyspepsia
| Article | Year |
|---|---|
Potential therapeutic benefit of ursodeoxycholic acid in the management of non hepato-biliary upper gastrointestinal disorders.
Topics: Adenomatous Polyposis Coli; Adult; Celecoxib; Drug Therapy, Combination; Dyspepsia; Humans; Ursodeox | 2023 |
An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Cohort Studies; Cycl | 2010 |
Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.
Topics: Abdominal Pain; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhi | 2003 |
Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Dyspepsia; Female; Gastric Mucosa; Helicobacter Infections; He | 2007 |